Ahead of its JPM20 presentation, GW Pharmaceuticals (NASDAQ:GWPH) announces preliminary 2019 results:
Q4 and full-year product sales should be ~$108M and ~$309M, respectively. Epidiolex sales should be ~$104M and ~$296M, respectively.
Final results will be released on February 25.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.